A NIAID-sponsored clinical trial of an mpox vaccine in adolescents found it was safe and generated an antibody response equivalent to that seen in adults, according to interim study results presented at the IDWeek2024 conference in Los Angeles. Adolescents are among the population groups affected by mpox in the current Clade I outbreak. The authors underscored the need to evaluate the vaccine in younger children to extend the evidence base to all people affected by mpox.
Mpox Vaccine Is Safe and Generates a Robust Antibody Response in Adolescents
Latest News
Dr. David Diemert, the director of the George Washington University Vaccine Research Unit, weighs in on President Donald Trump's executive order pushing for revisions to how children in the US are vaccinated and what that means for the future.
The GW VRU is a site for a clinical trial to examine Pfizer's new C. diff vaccine.
This was a phase 2, randomized, open-label, non-placebo controlled trial to evaluate two partial doses o the Modified Vaccinia Ankara-Bavarian Nordin (MVA-BN) vaccine for protection against mpox.
